NCT00623324View on ClinicalTrials.gov

The Effects of Aplindore on the Treatment of Signs and Symptoms of Parkinson's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

July 31, 2008

Conditions
Early Stage Parkinson's Disease
Interventions
DRUG

Aplindore

Tablets .05 - 5 mg BID dosing for 14 days

DRUG

Placebo

Placebo tablets to match the number of active tablets

Trial Locations (1)

33143

Miami Research Associates, Miami

Sponsors
All Listed Sponsors
lead

Ligand Pharmaceuticals

INDUSTRY

NCT00623324 - The Effects of Aplindore on the Treatment of Signs and Symptoms of Parkinson's Disease | Biotech Hunter | Biotech Hunter